Chubb Call Buyers Take Control Ahead of July Earnings
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Options traders are piling into calls on CB at an unprecedented rate. The put-call ratio has dropped to 0.58 — 3.06 standard deviations below its 20-day mean of 0.68. That's the lowest PCR reading in 52 weeks.
The signal is hard to ignore. Calls now outnumber puts by nearly two to one. Traders appear to be positioning ahead of Chubb's next earnings report, due July 21.
The Options Story
The PCR collapse has been swift. On June 12 it sat at 0.73. By June 24 it had fallen to 0.58. That's a sustained directional move, not a one-day anomaly.
The z-score of -3.06 puts current positioning in rare territory. Since May, the 52-week PCR low stands at 0.46. The current level is approaching that floor, with earnings still four weeks out.
Shorts Are Retreating Too
Short sellers have been heading for the exits. SI stands at 0.91% of free float — a low absolute level, and falling. Shares short dropped roughly 7% over the past week.
The borrow market reflects the same story. Cost to borrow has fallen 52% in a week to just 0.23%. Availability is extremely loose — over 200 million shares remain available to lend, a fraction of which are currently out on loan. There is no squeeze pressure here. Shorts are simply walking away.
What the Holders Signal
Berkshire Hathaway remains Chubb's largest disclosed institutional holder at 8.8% of shares — a position that has been unchanged in the most recent filing. FMR added over 1.3 million shares in the latest reported period. T. Rowe Price added 854,000. Capital Research added 739,000.
The bull case rests on Chubb's track record: combined ratios in the low 80s, consistent buybacks, and Evan Greenberg's long-tenured leadership. The bear case points to price-to-book at 1.48x, below-peer ROE expectations, and natural catastrophe risk.
Barclays trimmed its price target to $368 from $375 on June 12, maintaining Equal-Weight. The consensus mean target sits at $345 — roughly 3% above the current price of $335.
Data Summary
- PCR: 0.58, z-score -3.06, 52-week low territory
- SI % of Float: 0.91%, down ~7% week-on-week
- Cost to Borrow: 0.23%, down 52% in one week
- Borrow availability: extremely loose; 207M+ shares available
- Next earnings: July 21, 2026
- Price: $335.15, up 0.9% on the day, up 2.2% on the week
Against its peers
Shares moved +2.2% over the past week against a median of +2.9% for its closest peers.
Stocks in this article
See the live data behind this article on ORTEX.
Open CB on ORTEX →How this article was generated
- Generated
- 25 Jun 2026, 11:11
- Data as of
- 25 Jun 2026, 11:05
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.